Back to today’s briefing

Story perspectives

Aspirin Cuts Colorectal Cancer Recurrence in Key Patients

9/24/2025

50 10

Summary

Story summary

The ALASCCA trial found low-dose aspirin reduced colorectal cancer recurrence in patients with PIK3CA mutations (7.7% vs 14.1%-16.8%).
Disease-free survival for PIK3CA hotspot mutation patients rose from 81.4% to 88.5%.
Study enrolled 626 patients with stage I–III cancer across Sweden and Europe.
Aspirin’s anti-inflammatory action may slow tumor growth, but bleeding risks exist; findings support incorporating PIK3CA testing into guidelines.

1 of 1

Story summary

The ALASCCA trial found low-dose aspirin reduced colorectal cancer recurrence in patients with PIK3CA mutations (7.7% vs 14.1%-16.8%).
Disease-free survival for PIK3CA hotspot mutation patients rose from 81.4% to 88.5%.
Study enrolled 626 patients with stage I–III cancer across Sweden and Europe.
Aspirin’s anti-inflammatory action may slow tumor growth, but bleeding risks exist; findings support incorporating PIK3CA testing into guidelines.